Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

Sidler, Marc; Leach, Steven T.; Day, Andrew S.

doi:10.1002/ibd.20336

Cited by 135 publications

(160 citation statements)

References 34 publications

(44 reference statements)

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Sidler et al 82 compared FC with faecal S100A12, CRP and ESR. S100A12 is a protein from the same S100 family as calprotectin (which is a complex of S100A8 and S100A9).…”

Section: Results Of Clinical Effectiveness Reviewmentioning

confidence: 99%

“…However, this cannot be the sole explanation, because raised calprotectin levels have been reported in studies that exclude people using NSAIDs. 60,82 As noted in a previous assessment report for NICE, some people with IBS-D may have bile acid malabsorption.…”

Section: Inflammatory Irritable Bowel Syndrome?mentioning

confidence: 93%

“…182 This has resulted in the suggestion it is perhaps more specific than calprotectin in distinguishing inflammatory-related conditions compared with functional types, for example IBS. 82 However, both markers show correlation with endoscopic and histological inflammation. 183,184 The reported ranges for sensitivity with S100A12 are 86-97%) and specificity 92-100%.…”

Section: S100a12mentioning

confidence: 99%

See 2 more Smart Citations

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

236

201

View full text Add to dashboard Cite

“…Sidler et al 82 compared FC with faecal S100A12, CRP and ESR. S100A12 is a protein from the same S100 family as calprotectin (which is a complex of S100A8 and S100A9).…”

Section: Results Of Clinical Effectiveness Reviewmentioning

confidence: 99%

Section: Inflammatory Irritable Bowel Syndrome?mentioning

confidence: 93%

Section: S100a12mentioning

confidence: 99%

See 1 more Smart Citation

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

236

201

View full text Add to dashboard Cite

“…It has been suggested that an inflammatory mediator directly released into the gut lumen from the inflammatory process might be an ideal test to detect bowel inflammation in IBD (19). In many studies, fecal calprotectin has been claimed to be a specific, sensitive, non-invasive, cheap and accessible marker for gut inflammation (11,12,17). The fact that calprotectin is stable in room temperature for 5 days makes it more suitable for routine clinical studies (20).…”

Section: Figurementioning

confidence: 99%

“…It is present in neutrophils and monocytes and is released by activation of these cells in plasma, urine, stools and other media as a consequence of disease activity (9). Several studies reported that fecal calprotectin (FC) level is associated with invasive markers of gut inflammation such as 99Tc-labeled white cell scans and endoscopic and histologic inflammation scores (10).Recent studies showed FC is a specific, sensitive, non-invasive, cheap and accessible marker for gut inflammation (11)(12). The aims of the present study were to evaluate the clinical value of fecal calprotectin as a non invasive marker in differentiating organic from functional bowel diseases in correlation with endoscopic and histopathological examinations in Egyptian patients.…”

Section: Introductionmentioning

confidence: 99%

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Sheta

Salem

Ismail

et al. 2013

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Bowel diseases are very common, most of them are functional not organic in nature but clinicians suffer a lot in differentiating between the two categories especially the management is completely different. The symptoms of functional bowel diseases can be very similar to organic inflammatory bowel diseases like ulcerative colitis. In many cases the definitive diagnosis needs invasive procedures including lower colonoscopy and biopsy for histopathological documentation. Aim of the work: To evaluate the clinical value of fecal calprotectin as a non invasive marker differentiating organic from functional bowel diseases in correlation with endoscopic and histopathological examinations. Subjects and methods: The study included 40 patients, selected to represent 2 groups: group (I) included 20 patients with ulcerative colitis (UC) proved by colonoscopy and histopathology who further subdivided into sub-groups according to activity and site of involvement; and group (II) included 20 patients who had symptoms suggestive of irritable bowel syndrome (IBS) and in whom colonoscopy was found to be normal served as control. All participants were subjected to thorough history taking, physical examination and routine laboratory investigations. Calprotectin in feces was measured using the enzyme-linked immunosorbent assay (ELISA).Results: Fecal calprotectin concentration in the patients with UC was significantly higher than in patients with IBS (Mean values ± SD; 201.7 ± 46.7 μg/g vs, 22.3 ± 10.1 μg/g, P < 0.01). A significant difference was also found in the patients with active UC in comparison to UC patients without sign of activity (Mean values ± SD; 220.2 ± 31.1 μg/g vs, 167.3 ± 23.9 μg/g, P<0.05). The sensitivity of fecal calprotectin at cut off value 195.5 µg/g; as activity marker of UC was 82.2 % while its specificity was 85.7 %., Positive predictive value was 90.1% and negative predictive was 66.6%. Conclusion: Fecal calprotectin can differentiate with great acceptance between organic and functional bowel diseases and can be used as a rational fecal marker for intestinal inflammation in clinical practice. This kind of marker is relatively precise, simple and noninvasive and could give a crude idea about the activity of the lesions.

show abstract

Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children

et al. 2017

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Blood markers and fecal calprotectin are used in the diagnostic workup for inflammatory bowel disease (IBD) in pediatric patients. Any added diagnostic value of these laboratory markers remains unclear. OBJECTIVE To determine whether adding laboratory markers to evaluation of signs and symptoms improves accuracy when diagnosing pediatric IBD. DATA SOURCES A literature search of MEDLINE and EMBASE from inception through September 26, 2016. Studies were identified using indexing terms and free-text words related to child, target condition IBD, and diagnostic accuracy. STUDY SELECTION Two reviewers independently selected studies evaluating the diagnostic accuracy of more than 1 blood marker or fecal calprotectin for IBD, confirmed by endoscopy and histopathology or clinical follow-up, in pediatric patients with chronic gastrointestinal symptoms. Studies that included healthy controls and/or patients with known IBD were excluded. DATA EXTRACTION AND SYNTHESIS Individual patient data from each eligible study were requested from the authors. In addition, 2 reviewers independently assessed quality with Quality Assessment of Diagnostic Accuracy Studies-2. MEAN OUTCOMES AND MEASURES Laboratory markers were added as a single test to a basic prediction model based on symptoms. Outcome measures were improvement of discrimination by adding markers as a single test and improvement of risk classification of pediatric patients by adding the best marker. RESULTS Of the 16 eligible studies, authors of 8 studies (n = 1120 patients) provided their data sets. All blood markers and fecal calprotectin individually significantly improved the discrimination between pediatric patients with and those without IBD, when added to evaluation of symptoms. The best marker-fecal calprotectin-improved the area under the curve of symptoms by 0.26 (95% CI, 0.21-0.31). The second best marker-erythrocyte sedimentation rate-improved the area under the curve of symptoms by 0.16 (95% CI, 0.11-0.21). When fecal calprotectin was added to the model, the proportion of patients without IBD correctly classified as low risk of IBD increased from 33% to 91%. The proportion of patients with IBD incorrectly classified as low risk of IBD decreased from 16% to 9%. The proportion of the total number of patients assigned to the intermediate-risk category decreased from 55% to 6%. CONCLUSIONS AND RELEVANCE In a hospital setting, fecal calprotectin added the most diagnostic value to symptoms compared with blood markers. Adding fecal calprotectin to the diagnostic workup of pediatric patients with symptoms suggestive of IBD considerably decreased the number of patients in the group in whom challenges in clinical decision making are most prevalent.

show abstract

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

Cited by 135 publications

References 34 publications

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Value of Fecal Calprotectin as a Non-Invasive Marker Differentiating Organic From Functional Bowel Diseases

Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children

Contact Info

Product

Resources

About